<DOC>
	<DOCNO>NCT02535364</DOCNO>
	<brief_summary>This single-arm , multicenter Phase 2 trial treat adult patient relapse refractory B-ALL infusion patient 's T cell genetically modify express chimeric antigen receptor ( CAR ) bind leukemia cell express CD19 protein cell surface . The study determine modify T cell ( call JCAR015 ) help body 's immune system eliminate leukemia cell . The trial also study safety treatment JCAR015 , long JCAR015 cell stay patient 's body , extent JCAR015 eliminate minimal residual disease , impact treatment survival .</brief_summary>
	<brief_title>Study Evaluating Efficacy Safety JCAR015 Adult B-cell Acute Lymphoblastic Leukemia ( B-ALL )</brief_title>
	<detailed_description>This single-arm , multicenter Phase 2 study determine efficacy safety JCAR015 adult patient relapse refractory B-ALL . The study follow sequential phase : Part A ( screen , leukapheresis , cell product preparation , cytoreductive chemotherapy ) Part B ( treatment follow-up ) . The follow-up period participant approximately 12 month final JCAR015 infusion . The total duration study expect approximately 3 year . Long-term follow-up survival , toxicity , viral vector safety continue separate long-term follow-up protocol per health regulatory authority guideline , currently 15 year last JCAR015 infusion .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<criteria>1 . Age â‰¥ 18 year time consent 2 . Relapsed refractory BALL , define : First great bone marrow relapse CR , Any bone marrow relapse allogeneic hematopoietic stem cell transplant ( HSCT ) ; subject must least 100 day HSCT time screen immunosuppressant medication least 1 month time screening , active graftvshost disease ( GVHD ) , Refractory BALL , define achieve CR CRi two attempt remission induction use standard regimen , Ph+ BALL subject intolerant ineligible tyrosine kinase inhibitor ( TKI ) therapy , progress least one line TKI therapy 3 . Morphological evidence disease bone marrow ( least 5 % blast ) 4 . Evidence CD19 expression 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 time screen 6 . Adequate pulmonary , renal , hepatic , cardiac function 7 . Adequate central peripheral vascular access leukapheresis procedure 1 . Isolated extramedullary disease relapse 2 . Concomitant genetic syndrome know bone marrow failure syndrome 3 . Burkitt 's lymphoma/leukemia chronic myelogenous leukemia lymphoid blast crisis ( p210 BCRABL+ ) 4 . Prior malignancy , unless treat curative intent evidence active disease present &gt; 5 year screen 5 . Prior treatment gene therapy product 6 . Active hepatitis B , active hepatitis C , human immunodeficiency virus ( HIV ) infection time screen 7 . Systemic fungal , bacterial , viral , infection control , time screen 8 . Presence Grade IIIV ( Glucksberg ) BD ( IBMTR ) acute extensive chronic GVHD time screen 9 . Active central nervous system ( CNS ) involvement malignancy ( define CNS3 per National Comprehensive Cancer Network [ NCCN ] guideline ) 10 . History one follow cardiovascular condition within past 6 month : Class III IV heart failure define New York Heart Association ( NYHA ) , cardiac angioplasty stenting , myocardial infarction , unstable angina , clinically significant cardiac disease 11 . History presence clinically relevant CNS pathology epilepsy , generalized seizure disorder , paresis , aphasia , stroke , severe brain injury , dementia , Parkinson 's disease , cerebellar disease , organic brain syndrome , psychosis 12 . Participation investigational research study use investigational agent within 30 day screen 13 . History treatment murinederived biological product blinatumomab unless subject show negative humanantimouseantibodies ( HAMA ) prior screen 14 . Pregnant nursing woman 15 . Use prohibit medication : 1 . Steroids : Therapeutic dos corticosteroid prohibit within 7 day prior leukapheresis . 2 . Allogeneic cellular therapy : Donor lymphocyte infusion ( DLI ) prohibit within 4 week prior leukapheresis 3 . GVHD therapy : Any drug use GVHD within 4 week prior leukapheresis 4 . Chemotherapies : Salvage chemotherapy must stop least 1 week prior leukapheresis 16 . Treatment alemtuzumab within 6 month prior leukapheresis , treatment clofarabine cladribine within 3 month prior leukapheresis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>acute lymphoblastic leukemia</keyword>
	<keyword>ALL</keyword>
	<keyword>chimeric antigen receptor</keyword>
	<keyword>CAR</keyword>
	<keyword>CAR T cell</keyword>
	<keyword>JCAR015</keyword>
	<keyword>autologous T cell therapy</keyword>
	<keyword>cell therapy</keyword>
</DOC>